TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38876647

Group type: EXPERIMENTAL
Intervention: Manual therapy interventions (MTIs) including passive joint mobilisation and soft tissue manipulation, administered for eight weekly 30-min sessions.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Manual therapy interventions (MTIs)
Number of subjects: 15
Study: 38876657

Group type: EXPERIMENTAL
Intervention: Exercises combined with NMES (ESG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Exercises only (ExG)
Number of subjects: 34
Study: 38876748

Group type: EXPERIMENTAL
Intervention: Combined technique (stent retrievers plus contact aspiration)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Contact aspiration alone
Number of subjects: 521
Study: 38876800

Group type: EXPERIMENTAL
Intervention: Rectus sheath block with parasternal block
Number of subjects: 58

Group type: COMPARATOR
Intervention: Parasternal block with epigastric exit sites of chest drains receiving surgical infiltration of local anesthetic
Number of subjects: 58
Study: 38877036

Group type: EXPERIMENTAL
Intervention: ExPEC10V
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 38877077

Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby program (Cognitive Behavior Therapy)
Number of subjects: 796
Study: 38877325

Group type: EXPERIMENTAL
Intervention: Hyperbilirubinemia requiring phototherapy
Number of subjects: 1526

Group type: COMPARATOR
Intervention: No hyperbilirubinemia (Control)
Number of subjects: 1526
Study: 38877446

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Freeze-dried bone allograft (FDBA)
Number of subjects: 40
Study: 38877450

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection rectopexy (L-RRP) with mesh-sacrocolpopexy (L-SCP) using synthetic mesh (SM)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection rectopexy (L-RRP) with mesh-sacrocolpopexy (L-SCP) using biological mesh (BM)
Number of subjects: 44
Study: 38877464

Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin membrane + NanoBone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Platelet Rich Fibrin membrane
Number of subjects: 40
Study: 38877477

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (FBSF)
Number of subjects: 30
Study: 38877533

Group type: EXPERIMENTAL
Intervention: remimazolam
Number of subjects: 696

Group type: COMPARATOR
Intervention: propofol-based TIVA
Number of subjects: 696
Study: 38877571

Group type: COMPARATOR
Intervention: Haemoglobin values < 7.5 g/dL
Number of subjects: 1590

Group type: COMPARATOR
Intervention: Haemoglobin values between 7.5-9.5 g/dL
Number of subjects: 1590

Group type: EXPERIMENTAL
Intervention: Increase of haemoglobin value
Number of subjects: 1590

Group type: COMPARATOR
Intervention: Anaemia (Hb < 9.5 g/dL)
Number of subjects: 1590
Study: 38877595

Group type: EXPERIMENTAL
Intervention: Active tDCS group (20 min of 2.0-mA direct current to frontal lobes)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham tDCS group (30 s of stimulation to the frontal lobes)
Number of subjects: 34
Study: 38877608

Group type: EXPERIMENTAL
Intervention: Adapted Test-and-Exercise home-based exercise program (8 weeks, once per week with a physiotherapist, twice per week with caregiver or independently)
Number of subjects: 12
Study: 38877716

Group type: EXPERIMENTAL
Intervention: 0.05% NaF mouth rinse (226 ppm F)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Calcium prerinse followed by 0.05% NaF mouth rinse
Number of subjects: 20
Study: 38877762

Group type: EXPERIMENTAL
Intervention: DTG + FTC/TAF
Number of subjects: 340

Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 340
Study: 38877777

Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL) treatment
Number of subjects: 177
Study: 38877972

Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg once daily
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 38877993

Group type: EXPERIMENTAL
Intervention: Monofilament polydioxanone barbed suture, MONOFIX
Number of subjects: 30
Study: 38878007

Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1222
Study: 38878009

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 202
Study: 38878063

Group type: EXPERIMENTAL
Intervention: No intraabdominal drains
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intraabdominal drains
Number of subjects: 71
Study: 38878121

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: De novo patients
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: DRF-treated patients after re-baselining
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Patients not re-baselined
Number of subjects: 1057
Study: 38878145

Group type: EXPERIMENTAL
Intervention: Osimertinib population pharmacokinetic models
Number of subjects: 11
Study: 38878175

Group type: EXPERIMENTAL
Intervention: Serial PET scans at 5, 15, 30, 45, 60, and 120 min after intervention
Number of subjects: 21
Study: 38878207

Group type: EXPERIMENTAL
Intervention: TLD-1 (pegylated liposomal doxorubicin)
Number of subjects: 30
Study: 38878209

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg QD from Day 15 to Day 21
Number of subjects: 11

Group type: COMPARATOR
Intervention: Encorafenib 450 mg QD from Day 1
Number of subjects: 11

Group type: COMPARATOR
Intervention: Binimetinib 45 mg BID from Day 1
Number of subjects: 11
Study: 38878236

Group type: EXPERIMENTAL
Intervention: Fractional Er:YAG laser + Platelet-Rich Plasma (PRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Microneedling + Platelet-Rich Plasma (PRP)
Number of subjects: 40
Study: 38878337

Group type: EXPERIMENTAL
Intervention: Internet-based ACT combined with Treatment as Usual (iACT + TAU)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 103
Study: 38878692

Group type: EXPERIMENTAL
Intervention: Structured active play intervention
Number of subjects: 18
Study: 38878794

Group type: EXPERIMENTAL
Intervention: AZD2816 (4-week interval)
Number of subjects: 1449

Group type: COMPARATOR
Intervention: AZD1222
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: AZD2816 (12-week interval)
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: AZD1222-AZD2816
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: AZD2816 (4-week)
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: AZD2816 (12-week)
Number of subjects: 1449
Study: 38878969

Group type: EXPERIMENTAL
Intervention: Presence of intraplaque hemorrhage (IPH)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: IPH SIR
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: IPH volume
Number of subjects: 89
Study: 38878996

Group type: EXPERIMENTAL
Intervention: Adaptive design, semi-structured intervention with quarterly leader-employee check-ins and training modules
Number of subjects: 12

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adaptive design, semi-structured intervention
Number of subjects: 12
Study: 38878997

Group type: EXPERIMENTAL
Intervention: TOPPS intervention (values-based, behavioral activation intervention)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Health Education (HE) control condition
Number of subjects: 250
Study: 38879045

Group type: EXPERIMENTAL
Intervention: Through-the-needle injection-capable electrosurgical knife
Number of subjects: 579
Study: 38879382

Group type: EXPERIMENTAL
Intervention: 2 to 6 metastatic mesogastria
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: 1 metastatic mesogastrium
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: No lymph node metastasis
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Metastatic mesogastria
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: N stages
Number of subjects: 479
Study: 38879393

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (cohort 1)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (cohort 2)
Number of subjects: 109
Study: 38879455

Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) pulse oximetry combining oxygenation, perfusion data, and pulse delay at 2 time points
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ML algorithms at 1 versus 2 time points with/without pulse delay
Number of subjects: 6
Study: 38879462

Group type: EXPERIMENTAL
Intervention: Perivascular adipose tissue attenuation around LIMA in situ
Number of subjects: 573

Group type: COMPARATOR
Intervention: Perivascular adipose tissue attenuation around native coronary arteries
Number of subjects: 573
Study: 38879476

Group type: EXPERIMENTAL
Intervention: PET imaging for radiotherapy planning
Number of subjects: 0
Study: 38879506

Group type: EXPERIMENTAL
Intervention: Hemodynamic management with HPI guidance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care treatment
Number of subjects: 60
Study: 38879518

Group type: EXPERIMENTAL
Intervention: Delayed Cold-Stored Platelets (DCSP) - ABO-identical, buffy-coat, pathogen-reduced platelets in platelet additive solution maintained at 22 °C for up to 4 days then placed at 4 °C for a minimum of 24 h, with expiration at 14 days after collection. Duration: from termination of cardiopulmonary bypass to 24 h after, with a maximum of two doses.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Room Temperature Platelets (RTP) - standard of care control group.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: DCSP
Number of subjects: 50
Study: 38879520

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both SG and RYGB
Number of subjects: 26
Study: 38879532

Group type: EXPERIMENTAL
Intervention: ACP care pathway implementation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ACP care pathway structure and tools
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Integration of ACP pathway with current practice
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Support for ACP and the pathway
Number of subjects: 13
Study: 38879559

Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 38

Group type: COMPARATOR
Intervention: SG
Number of subjects: 38
Study: 38879561

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team conferences (MDTs)
Number of subjects: 112
Study: 38879571

Group type: EXPERIMENTAL
Intervention: 200 mg Pycnogenol® daily for 12 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo daily for 12 weeks
Number of subjects: 150
Study: 38879802

Group type: EXPERIMENTAL
Intervention: Linvoseltamab 200 mg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Linvoseltamab 50 mg
Number of subjects: 221
Study: 38879879

Group type: EXPERIMENTAL
Intervention: SPS tablets (n = 60; three tablets per dose, twice daily) for 24 weeks
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (n = 61) for 24 weeks
Number of subjects: 121
Study: 38880111

Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M vaccine candidate (10 μg RH5.1 at 0, 1, and 2 months for Adults 10M; 50 μg RH5.1 at 0 and 1 month and 10 μg RH5.1 at 6 months for Adults DFx; 10 μg RH5.1 at 0, 1, and 2 months for Children 10M; 10 μg RH5.1 at 0, 1, and 6 months for Children 10D; Children DFx and High Children DFx with dose-escalation regimen)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Delayed third dose regimen (Children 10D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M vaccine candidate
Number of subjects: 60
Study: 38880172

Group type: EXPERIMENTAL
Intervention: EGFR mutations
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: EGFR mutation subtypes
Number of subjects: 601

Group type: COMPARATOR
Intervention: Nonsmoking status
Number of subjects: 601

Group type: COMPARATOR
Intervention: Stage of NSCLC
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Age, gender, ethnicity
Number of subjects: 601

Group type: COMPARATOR
Intervention: Smoking history and stage III disease
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Systemic adjuvant therapy
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Number of subjects: 601
Study: 38880174

Group type: EXPERIMENTAL
Intervention: Refined corn meal + corn bran (RCM + B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Whole-grain corn meal
Number of subjects: 36

Group type: COMPARATOR
Intervention: Refined corn meal (RCM)
Number of subjects: 36
Study: 38880198

Group type: EXPERIMENTAL
Intervention: High-dose (200 ppm for 30 min) + continuous low-dose (20 ppm) iNO
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intermittent high-dose iNO
Number of subjects: 20
Study: 38880251

Group type: EXPERIMENTAL
Intervention: dupilumab 300 mg every 2 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 89
Study: 38880279

Group type: EXPERIMENTAL
Intervention: Primary ciliary dyskinesia (PCD)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Presence of upper airway disease (chronic rhinosinusitis and/or nasal polyps)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Age < 53 years
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Radiologic involvement of any middle and lower lobe
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Duration of bronchiectasis > 15 years
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: History of Pseudomonas aeruginosa isolation from respiratory specimen
Number of subjects: 1000
Study: 38880785

Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF/RSV preF protein vaccine (1 × 10 dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF/RSV preF protein vaccine
Number of subjects: 0
Study: 38880822

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 2604
Study: 38880902

Group type: EXPERIMENTAL
Intervention: One-stage endoscopic middle meatal antrostomy (EMMA) with the application of platelet-rich fibrin (PRF) membranes and acrylic splint
Number of subjects: 9
Study: 38880932

Group type: EXPERIMENTAL
Intervention: BI 474121 (3.0 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 474121
Number of subjects: 0
Study: 38880954

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI), 30-min sessions, three times a week for 8 weeks during haemodialysis
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study: 38880956

Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 or 10 mg twice daily)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 1202
Study: 38881232

Group type: EXPERIMENTAL
Intervention: Young patients (yCRC)
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Elderly patients (eCRC)
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: Both groups (yCRC and eCRC)
Number of subjects: 1599
Study: 38881252

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38881370

Group type: EXPERIMENTAL
Intervention: Edoxaban management during periprocedural period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38881386

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 0
Study: 38881397

Group type: EXPERIMENTAL
Intervention: Staff-assisted peritoneal dialysis (PD)
Number of subjects: 121
Study: 38881460

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (target <120 mm Hg)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Standard blood pressure control (target <140 mm Hg)
Number of subjects: 502
Study: 38881506

Group type: EXPERIMENTAL
Intervention: Heplisav-B (HepB-CpG) 2-dose series
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Heplisav-B (HepB-CpG) 1-dose
Number of subjects: 96
Study: 38881599

Group type: EXPERIMENTAL
Intervention: EYP-1901 (440 μg, 1030 μg, 2060 μg, 3090 μg)
Number of subjects: 17
Study: 38881600

Group type: EXPERIMENTAL
Intervention: PRIMA neurostimulation system with a subretinal microchip
Number of subjects: 5
Study: 38881832

Group type: EXPERIMENTAL
Intervention: Spatial-to-Temporal Attention Module (STAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Facial features only
Number of subjects: 0
Study: 38881900

Group type: EXPERIMENTAL
Intervention: Cibisatamab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monoclonal anti-idiotypic (anti-ID) antibody positive controls
Number of subjects: 0
Study: 38882206

Group type: EXPERIMENTAL
Intervention: High postexercise cTn concentrations (n=100)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Low postexercise cTn concentrations (n=50)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Entire cohort (n=1500)
Number of subjects: 1500
Study: 38882443

Group type: EXPERIMENTAL
Intervention: Hetrombopag
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 38882712

Group type: EXPERIMENTAL
Intervention: Walking stress test
Number of subjects: 24
Study: 38883150

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID monotherapy
Number of subjects: 1000
Study: 38883163

Group type: EXPERIMENTAL
Intervention: Integrated analysis of genetic, epigenetic, and immunophenotypic landscape
Number of subjects: 61
Study: 38883706

Group type: EXPERIMENTAL
Intervention: CONCERN Early Warning System (EWS) intervention
Number of subjects: 60893

Group type: COMPARATOR
Intervention: usual-care
Number of subjects: 60893
Study: 38883737

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF) with fluoride varnish
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Sealants and atraumatic restorations (ART) with fluoride varnish
Number of subjects: 1083
Study: 38883740

Group type: EXPERIMENTAL
Intervention: Ribociclib (CDK4/6 inhibitor) and Everolimus (mTOR inhibitor)
Number of subjects: 24
Study: 38883743

Group type: EXPERIMENTAL
Intervention: Self-administered intravaginal 5% fluorouracil (5FU) cream, 2g every other week for eight applications.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Self-administered intravaginal 5% fluorouracil (5FU) cream
Number of subjects: 12
Study: 38883760

Group type: EXPERIMENTAL
Intervention: Game-based rehabilitation program with scaffolding (17 subjects)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Game-based rehabilitation program without scaffolding (16 subjects)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (combined)
Number of subjects: 33
Study: 38883767

Group type: EXPERIMENTAL
Intervention: Preoperative physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38883779

Group type: EXPERIMENTAL
Intervention: Intratumoral administration of anti-CD40 agonistic antibody (2141-V11)
Number of subjects: 10
Study: 38883789

Group type: EXPERIMENTAL
Intervention: Standardized sexual dysfunction (SD) screening intervention
Number of subjects: 86
Study: 38883792

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI)
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Risk score based on identified parameters
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Risk score used prospectively in external French cohort
Number of subjects: 748
Study: 38883796

Group type: EXPERIMENTAL
Intervention: Retention strategies implemented by the TEDDY Study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unique retention strategies of TEDDY
Number of subjects: 0
Study: 38884175

Group type: EXPERIMENTAL
Intervention: Crovalimab
Number of subjects: 204

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 204
Study: 38884254

Group type: EXPERIMENTAL
Intervention: Futibatinib
Number of subjects: 0
Study: 38884324

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg, max 25 mg)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 516
Study: 38884332

Group type: EXPERIMENTAL
Intervention: Reteplase (18 mg bolus followed by another 18 mg bolus 30 minutes later)
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg, max 90 mg)
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1412
Study: 38884347

Group type: EXPERIMENTAL
Intervention: Community-based intervention (34 communities)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Wait-list control (33 communities)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Intervention (34 communities)
Number of subjects: 67
Study: 38884415

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis (not specified in detail)
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: Inappropriate thromboprophylaxis practices
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: Specialized clinical pathway for thromboprophylaxis
Number of subjects: 1836
Study: 38884880

Group type: EXPERIMENTAL
Intervention: Medication optimization intervention
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 285
Study: 38884900

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Treatment of physician's choice (TPC)
Number of subjects: 213
Study: 38884967

Group type: EXPERIMENTAL
Intervention: MRT plus FIs
Number of subjects: 126

Group type: COMPARATOR
Intervention: MRT
Number of subjects: 126
Study: 38884982

Group type: EXPERIMENTAL
Intervention: Povidone iodine in alcohol
Number of subjects: 3360

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate in alcohol
Number of subjects: 3360

Group type: EXPERIMENTAL
Intervention: Povidone iodine in alcohol (cardiac surgery)
Number of subjects: 3360

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate in alcohol (cardiac surgery)
Number of subjects: 3360

Group type: EXPERIMENTAL
Intervention: Povidone iodine in alcohol (abdominal surgery)
Number of subjects: 3360

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate in alcohol (abdominal surgery)
Number of subjects: 3360
Study: 38884987

Group type: EXPERIMENTAL
Intervention: Nicotine-containing electronic cigarettes (ECs) 18 mg/mL with placebo tablets
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Varenicline with standard dosing and nicotine-free ECs
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo tablets with nicotine-free ECs
Number of subjects: 458